These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30381043)

  • 1. A comparative study of contamination in three closed systems for the preparation of hazardous drugs through simulations with fluorescein.
    González-Haba-Peña E; Manrique-Rodríguez S; Herranz-Alonso AM; Iglesias-Peinado I; Sanjurjo-Sáez M
    Farm Hosp; 2018 Nov; 42(6):234-238. PubMed ID: 30381043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of preparation of hazardous drugs with different closed-system drug transfer devices by means of simulation with fluorescein.
    González-Haba Peña E; Manrique Rodríguez S; Herranz Alonso AM; Pérez Castán P; Moreno Gálvez M; Iglesias Peinado I; Sanjurjo Saez M
    Farm Hosp; 2016 Nov; 40(n06):496-503. PubMed ID: 27894224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of two closed-system drug transfer device in the antineoplastic drug elaboration process].
    Gómez-Álvarez S; Porta-Oltra B; Hernandez-Griso M; Pérez-Labaña F; Climente-Martí M
    Farm Hosp; 2016 Jan; 40(1):36-43. PubMed ID: 26882832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PhaSeal® system: impact of its use on workplace contamination and duration of chemotherapy preparation.
    Favier B; Labrosse H; Gilles-Afchain L; Cropet C; Perol D; Chaumard N; Latour JF; Hild P
    J Oncol Pharm Pract; 2012 Mar; 18(1):37-45. PubMed ID: 21422148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe Cytotoxic Drug Preparation Using Closed-system Transfer Device: Technical and Practical Evaluation of a New Device (Vialshield/Texium) Comparatively to a Reference One (Phaseal).
    Garrigue P; Montana M; Ventre C; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Int J Pharm Compd; 2016; 20(2):148-54. PubMed ID: 27323425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and appreciation of two methods aiming at reducing hazardous drug environmental contamination: The centralization of the priming of IV tubing in the pharmacy and use of a closed-system transfer device.
    Guillemette A; Langlois H; Voisine M; Merger D; Therrien R; Mercier G; Lebel D; Bussières JF
    J Oncol Pharm Pract; 2014 Dec; 20(6):426-32. PubMed ID: 24395542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of surface contamination with cyclophosphamide and fluorouracil using a closed-system drug transfer device versus standard preparation techniques.
    Harrison BR; Peters BG; Bing MR
    Am J Health Syst Pharm; 2006 Sep; 63(18):1736-44. PubMed ID: 16960258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device.
    Siderov J; Kirsa S; McLauchlan R
    J Oncol Pharm Pract; 2010 Mar; 16(1):19-25. PubMed ID: 19965949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns and characteristics associated with surface contamination of hazardous drugs in hospital pharmacies.
    Salch SA; Zamboni WC; Zamboni BA; Eckel SF
    Am J Health Syst Pharm; 2019 Apr; 76(9):591-598. PubMed ID: 31361828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of surface contamination in a hospital hematology--oncology pharmacy.
    Touzin K; Bussières JF; Langlois E; Lefebvre M
    J Oncol Pharm Pract; 2009 Mar; 15(1):53-61. PubMed ID: 18772214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous training program for technicians handling antineoplastic drugs and occupational exposure risk].
    Dussart C; Favier B; Gilles L; Camal I; Almeras D; Latour JF; Grelaud G
    Bull Cancer; 2008 Sep; 95(9):821-2. PubMed ID: 18829414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States.
    Connor TH; Anderson RW; Sessink PJ; Broadfield L; Power LA
    Am J Health Syst Pharm; 1999 Jul; 56(14):1427-32. PubMed ID: 10428450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and evaluation of a novel product to remove surface contamination of hazardous drugs.
    Cox J; Speed V; O'Neal S; Hasselwander T; Sherwood C; Eckel SF; Zamboni WC
    J Oncol Pharm Pract; 2017 Mar; 23(2):103-115. PubMed ID: 26673538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter evaluation of a new closed system drug-transfer device in reducing surface contamination by antineoplastic hazardous drugs.
    Bartel SB; Tyler TG; Power LA
    Am J Health Syst Pharm; 2018 Feb; 75(4):199-211. PubMed ID: 29339374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of Contamination with Antibiotics on Surfaces and in Environmental Air in Three European Hospitals Following Implementation of a Closed-System Drug Transfer Device.
    Sessink PJM; Nyulasi T; Haraldsson ELM; Rebic B
    Ann Work Expo Health; 2019 Apr; 63(4):459-467. PubMed ID: 30852616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the new handling recommendations for hazardous drugs in a hospital pharmacy service.
    García-Alcántara BG; Perelló Alomar C; Moreno Centeno E; Modamio P; Mariño EL; Delgado Sánchez O
    Farm Hosp; 2017 Mar; 41(2):257-269. PubMed ID: 28236800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Closed System Drug Transfer Devices in Reducing Leakage during Antineoplastic Drugs Compounding.
    Piccardo MT; Forlani A; Izzotti A
    Int J Environ Res Public Health; 2021 Jul; 18(15):. PubMed ID: 34360250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost savings realized by use of the PhaSeal(®) closed-system transfer device for preparation of antineoplastic agents.
    Edwards MS; Solimando DA; Grollman FR; Pang JL; Chasick AH; Hightman CM; Johnson AD; Mickens MG; Preston LM
    J Oncol Pharm Pract; 2013 Dec; 19(4):338-47. PubMed ID: 23975556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and reduction of hazardous drug surface contamination through the use of a novel closed-system transfer device coupled with a point-of-care hazardous drug detection system.
    Brechtelsbauer E
    Am J Health Syst Pharm; 2023 Mar; 80(7):435-444. PubMed ID: 36370411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of closed systems in the Hospital Pharmacy.
    Forte Pérez-Minayo M; Castillo Bazán E; Hernández Segurado M; Arias Moya MÁ; Pelegrín Torres P; Bécares Martínez FJ
    Farm Hosp; 2016 Mar; 40(2):102-10. PubMed ID: 26980168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.